7/18/2012 7:06:38 AM
The most commonly prescribed multiple sclerosis drugs, including those made by Biogen Idec Inc. (BIIB) (BIIB), Bayer AG (BAYN) and Merck KGaA, failed to slow disability progression in a long-term study that raises new questions on whether the treatments can achieve that goal. Researchers compared historical outcomes for MS patients in British Columbia to assess the use of interferon beta drugs. The results, published online in the Journal of the American Medical Association, found the medicines didn’t delay progress of the patients’ disability.
comments powered by